Prof. Dr. Michael Sticherling

Professur für Dermatologie

Systemic treatments in pediatric and adolescent dermatology Systemtherapien bei Kindern und Jugendlichen in der Dermatologie (2025) Sticherling M, Süßmuth K Journal article Serum extracellular matrix biomarkers in rheumatoid arthritis, psoriatic arthritis and psoriasis and their association with hand function (2025) Port H, Coppers B, Tragl S, Manger E, Niemiec LM, Bayat S, Simon D, et al. Journal article, Original article Zinc deficiency-associated dermatitis in a prematurely born infant (2025) Grötsch J, Sticherling M Journal article Analysis of the German Compassionate Use Program on spesolimab in patients with generalized pustular psoriasis: evidence outside of clinical trials (2024) Krefting F, Welzel J, Thamm J, Thölken K, Wohlrab J, Müller VL, Kreuter A, et al. Journal article Baker's asthma due to liquorice production? Bäckerasthma bei der Lakritzherstellung? (2024) Azem T, Sticherling M, Berking C, Wagner N Journal article 100 years of academic dermatology in Erlangen: An example of the emancipation of dermatology 100 Jahre Universitätshautklinik in Erlangen: Ein Beispiel für die Emanzipierung des Faches Dermatologie (2024) Sticherling M, Berking C Journal article Unveiling Metabolic Similarities of Entheses in Patients with Psoriasis and Psoriatic Arthritis Using Noninvasive In Vivo Molecular Imaging: Results From a Cross-sectional Exploratory Study (2024) Fagni F, Tascilar K, Noversa de Sousa R, Bayat S, Sollfrank L, Kleyer A, Sticherling M, et al. Journal article Anatomical pattern of entheseal and synovial fibroblast activation in patients with psoriasis and its risk of developing psoriatic arthritis (2024) Corte G, Atzinger A, Temiz SA, Noversa de Sousa R, Mutlu MY, Schönau V, Raimondo MG, et al. Journal article Secukinumab in adult patients with lichen planus: efficacy and safety results from the randomized placebo-controlled proof-of-concept PRELUDE study. (2024) Passeron T, Reinhardt M, Ehst B, Weiss J, Sluzevich J, Sticherling M, Reygagne P, et al. Journal article Guselkumab demonstrates long-term efficacy and maintenance of treatment response postwithdrawal in systemic treatment-naïve patients and nonresponders to fumaric acid esters: results from parts II and III of a randomized active-comparator-controlled phase IIIb trial (POLARIS). (2024) Thaçi D, Pinter A, Sebastian M, Termeer C, Sticherling M, Gerdes S, Schäkel K, et al. Journal article